Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Undeterred By Upcoming Singulair Loss; Focuses On Phase III

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck reports second quarter earnings, looking past the patent expiration of Singulair to the drugs it icurrently is developing to replace the revenues it is expected to lose.

You may also be interested in...



How Low Does Merck Need To Go? FDA Safety Concerns May Cut Suvorexant’s Dosing

FDA will ask an advisory committee whether Merck’s insomnia drug should employ the tiered dosing schedule proposed for the elderly and non-responders, but the agency seems inclined towards a dose even lower that the ones that were used in Phase III.

Merck’s Suvorexant To Face FDA Panel Scrutiny On Next-Day Driving Effects

The Peripheral and Central Nervous System Drugs Advisory Committee’s May 22 review of the first-in-class insomnia drug will include data from two studies assessing the compound’s residual effects on next-day driving.

Merck Insomnia Drug Shows Improvements; Filing On Track

Merck is confident it can compete in the highly generic insomnia market; Phase III results show the insomnia drug suvorexant may have further benefits for patients.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074447

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel